Source link : https://www.newshealth.biz/health-news/glp-1-kidney-benefits-seen-with-or-without-sglt2-inhibitors/
New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), suggests that these benefits are consistent whether patients are or are not also treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors. The results […]
Author : News Health
Publish date : 2024-06-25 17:17:18
Copyright for syndicated content belongs to the linked Source.
Categories